Laxmi Organic Industries Ltd Q3 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 26 Aug 2026 | Chemicals & Petrochemicals | Market Cap: ₹4.8K Cr
Laxmi Organic targets doubling sales from INR 2,800 crores in FY '24 to FY '28, driven by INR 1,100 crores planned capex (Page 8). Laxmi Organic targets strong profitable volume and EBITDA growth through FY '25 and beyond, driven by operational excellence and new product launches.
From Laxmi Organic Industries Ltd's Q3 FY25 earnings-call transcript · updated 26 Aug 2026.
Price
₹170
Market Cap
₹4.8K Cr
P/E Ratio
38.3
How does Laxmi Organic Industries Ltd rank in Chemicals & Petrochemicals?
Compare Laxmi Organic Industries Ltd against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.
Laxmi Organic Industries Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹735 Cr, net profit ₹22 Cr.
Full financials →📊 Revenue & Sales Performance
- →Laxmi Organic targets doubling sales from INR 2,800 crores in FY '24 to FY '28, driven by INR 1,100 crores planned capex (Page 8).
- →Fluoro-intermediates business is expected to reach 40%-60% of a peak revenue of INR 200 crores by FY '26 (Pages 6, 8).
- →Specialty business pipeline remains strong with 11+ products, 60% fluoro-heavy, 40% other derivatives; focus on commercialization and capex for growth (Page 9).
- →Export growth is positive, with 36% of overall sales, helping derisk currency impact (Page 5).
- →Operational excellence efforts expected to sustain volume growth in both Essentials and Specialty segments (Pages 5, 10, 12).
- →Growth in CASE industry, pigments, and pharma segments supported by global MNC clients (Page 6).
- →Agro segment currently weak but anticipated to recover over time (Page 9).
📈 Profitability & Margins
- →Laxmi Organic targets strong profitable volume and EBITDA growth through FY '25 and beyond, driven by operational excellence and new product launches.
- →The Fluoro-Intermediate project at Lote is expected to achieve 40%-60% of peak revenues (INR 200 crores peak revenue) by FY '26, with targeted EBITDA margins of 20%-25%.
- →The INR 1,100 crores capex plan aims to double sales from INR 2,800 crores in FY '24 to FY '28, with Essentials business EBITDA margins of 8%-12% and Specialty margins of 20%-25%.
- →The company expects margins to improve due to better product mix, operational efficiencies, and stable raw material prices.
- →Sustainability ratings and safety recognitions reflect strong governance and can support long-term performance.
- →Overall growth is expected with doubled sales by FY '28 and improving EBITDA margins, positioning the company for strong earnings and EPS expansion.
🏗️ Capital Expenditure Plans
- →Total planned capex of INR 1,100 crores beyond the earlier Fluoro intermediate project.
- →INR 800 crores allocated for the Dahej site, including n-Butyl acetate.
- →INR 90 crores for a world-scale Ethyl Acetate plant at Lote.
- →INR 50 crores incremental capex pending for the Fluoro-intermediate project.
- →Additional smaller refurbishment capex for n-propyl acetate at existing sites.
- →Midpoint of expenditure for Dahej-related capex expected in the first half of FY '26.
- →Total Fluoro-intermediate project cost to complete is INR 550 crores (INR 500 crores already spent).
- →Expected to double sales from INR 2,800 crores in FY '24 to FY '28 driven by ongoing capex.
- →Emphasis on operational excellence, capacity augmentation, and customer centricity to drive growth.
- →Robust project tracking under CTO leadership for transparency and timely execution.
💰 Fundraising & Capital Structure
- →There is no mention of any current or future fundraising through debt or equity in the provided transcript.
- →The company is focused on executing its existing capex plans totaling INR 1,100 crores, primarily funded through internal resources.
- →INR 800 crores of the capex is allocated for the Dahej site, INR 50 crores for the Fluoro-intermediate project (pending completion), INR 90 crores for world-scale ethyl acetate, and a portion for refurbishment and upgrades.
- →Leadership emphasized disciplined project tracking under a Chief Technology Officer without indicating plans for raising external capital.
- →No explicit discussions or announcements regarding new debt or equity fundraising were made during the call.
📋 Order Book & Pipeline
- →The pipeline for new business remains strong and is getting revitalized.
- →Approximately 60% of the new business pipeline is focused on fluoro-related products.
- →The remaining 40% of the pipeline consists of other chemical derivatives.
- →The company is diligently working on commercializing these products and securing capex to monetize the pipeline.
- →The fluoro-intermediates project at the Lote site is targeting about 10% of peak revenues in Q4 and aims for 40%-60% of peak revenues by FY '26.
- →All key products contributing to FY '26 revenues have been successfully commercialized at the Lote facility.
Key Metrics
Frequently Asked Questions
What were Laxmi Organic Industries Ltd Q3 FY25 results?
Laxmi Organic targets doubling sales from INR 2,800 crores in FY '24 to FY '28, driven by INR 1,100 crores planned capex (Page 8). Laxmi Organic targets strong profitable volume and EBITDA growth through FY '25 and beyond, driven by operational excellence and new product launches.
What is Laxmi Organic Industries Ltd share price analysis?
Laxmi Organic Industries Ltd currently shows a neutral. The stock trades at a P/E of 38.3 with a market cap of ₹4,814 Cr. Investors should review the full earnings analysis for detailed insights.
Is Laxmi Organic Industries Ltd planning capital expenditure?
Total planned capex of INR 1,100 crores beyond the earlier Fluoro intermediate project.
Keep Laxmi Organic Industries Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.